U.S. market Closed. Opens in 19 hours 53 minutes

BMY | Bristol-Myers Squibb Company Stock Overview

(Stock Exchange: NYSE)
Day's Range 57.01 - 57.77
52 Week Range 39.35 - 61.08
Beta 0.45
Implied Volatility 21.83%
IV Rank 8.98%
Day's Volume 3,652,751
Average Volume 11,627,301
Shares Outstanding 2,028,180,000
Market Cap 116,376,968,400
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 1972-06-01
Valuation
Profitability
Growth
Health
P/E Ratio -16.03
Forward P/E Ratio 8.02
EPS -3.58
1YR Price Target 80.00
Dividend Yield 4.33%
Dividend Per Share 1.64
Dividend ExDate 2023-04-06
Dividend PayDate 2023-05-01
Employees 34,100
Country USA
Website BMY
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
BMY's peers: ABBV, ABT, AMGN, AMRN, AZN, BIIB, MRK, GILD, JNJ, LLY, PFE, GRFS, GSK, NVS, OGN, SNY, SCLX
*Chart delayed
Analyzing fundamentals for BMY we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see BMY Fundamentals page.

Watching at BMY technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on BMY Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙